Potential candidate camelid antibodies for the treatment of protein-misfolding diseases

Journal of Neuroimmunology

Volumn 272, Issue 1-2, 2014, Pages 76-85

  David, Monique Antoinette ^b,c   Jones, Daryl Rhys ^d   Tayebi, Mourad ^a,b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c Antibody Discovery Laboratory   (United States)

^d MAYO CLINIC   (United States)

Author keywords

A ; Camelid antibodies; Immunotherapy; Prions; Protein Misfolding Diseases; Tau

Indexed keywords

AMYLOID BETA PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ICSM 35; MONOCLONAL ANTIBODY PRIOAD12; MONOCLONAL ANTIBODY PRIOAD120; MONOCLONAL ANTIBODY PRIOAD13; MONOCLONAL ANTIBODY PRIOV3; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DROMEDARY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROTOXICITY; NONHUMAN; PRION; PRIORITY JOURNAL;

AΒ; CAMELID ANTIBODIES; IMMUNOTHERAPY; PRIONS; PROTEIN MISFOLDING DISEASES; TAU;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIGENS, CD; BLOOD-BRAIN BARRIER; BRAIN; CAMELS; CELL LINE, TUMOR; CLATHRIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; MICE; NEUROTOXICITY SYNDROMES; PEPTIDES; PROTEOSTASIS DEFICIENCIES; PRPSC PROTEINS; RECEPTORS, TRANSFERRIN; TAU PROTEINS; TIME FACTORS;

EID: 84901984624     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.05.001     Document Type: Article

References (35)

1. Abulrob A., Sprong H., Van Bergen En Henegouwen P., Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 2005, 95:1201-1214.
2. Bate C., Tayebi M., Diomede L., Salmona M., Williams A. Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines. PLoS ONE 2009, 4:e8221.
3. Beringue V., Mallinson G., Kaisar M., Tayebi M., Sattar Z., Jackson G., Anstee D., Collinge J., Hawke S. Regional heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 2003, 126:2065-2073.
4. Borchelt D.R., Taraboulos A., Prusiner S.B. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J. Biol. Chem. 1992, 267:16188-16199.
5. Cardinale A., Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol. Med. 2008, 14:373-380.
6. Cardinale A., Filesi I., Vetrugno V., Pocchiari M., Sy M.S., Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J. Biol. Chem. 2005, 280:685-694.
7. Conrath K.E., Lauwereys M., Galleni M., Matagne A., Frere J.M., Kinne J., Wyns L., Muyldermans S. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob. Agents Chemother. 2001, 45:2807-2812.
8. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., De Baetselier P., Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int. J. Cancer 2002, 98:456-462.
9. Desmyter A., Decanniere K., Muyldermans S., Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 2001, 276:26285-26290.
10. Donofrio G., Heppner F.L., Polymenidou M., Musahl C., Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J. Virol. 2005, 79:8330-8338.
11. Dumoulin M., Dobson C.M. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 2004, 86:589-600.
12. Dumoulin F., Lafont D., Boullanger P., Mackenzie G., Mehl G.H., Goodby J.W. Self-organizing properties of natural and related synthetic glycolipids. J. Am. Chem. Soc. 2002, 124:13737-13748.
13. Els Conrath K., Lauwereys M., Wyns L., Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 2001, 276:7346-7350.
14. Enari M., Flechsig E., Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9295-9299.
15. Genoud N., Ott D., Braun N., Prinz M., Schwarz P., Suter U., Trono D., Aguzzi A. Antiprion prophylaxis by gene transfer of a soluble prion antagonist. Am. J. Pathol. 2008, 172:1287-1296.
16. Giaccone G., Canciani B., Puoti G., Rossi G., Goffredo D., Iussich S., Fociani P., Tagliavini F., Bugiani O. Creutzfeldt-Jakob disease: Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein. Brain Pathol. 2000, 10:31-37.
17. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
18. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3353-3357.
19. Jones D.R., Taylor W.A., Bate C., David M., Tayebi M. A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell lines. PLoS ONE 2010, 5:e9804.
20. Kascsak R. Reiterating the epitope specificity of prion-specific mAb 3F4. J. Biol. Chem. 2010, 285. (le5, author reply le6).
21. Kascsak R.J., Rubenstein R., Merz P.A., Tonna-Demasi M., Fersko R., Carp R.I., Wisniewski H.M., Diringer H. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J. Virol. 1987, 61:3688-3693.
22. Muruganandam A., Tanha J., Narang S., Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002, 16:240-242.
23. Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol. 2001, 74:277-302.
24. Muzykantov V.R., Balyasnikova I.V., Joshi A., Fisher A.B., Smirnov M.D., Esmon N.L., Esmon C.T. Epitope-dependent selective targeting of thrombomodulin monoclonal antibodies to either surface or intracellular compartment of endothelial cells. Drug Deliv. 1998, 5:197-206.
25. Nguyen V.K., Desmyter A., Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv. Immunol. 2001, 79:261-296.
26. Polymenidou M., Moos R., Scott M., Sigurdson C., Shi Y.Z., Yajima B., Hafner-Bratkovic I., Jerala R., Hornemann S., Wuthrich K., Bellon A., Vey M., Garen G., James M.N., Kav N., Aguzzi A. The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS ONE 2008, 3:e3872.
27. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
28. Tagliabue E., Centis F., Campiglio M., Mastroianni A., Martignone S., Pellegrini R., Casalini P., Lanzi C., Menard S., Colnaghi M.I. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int. J. Cancer 1991, 47:933-937.
29. Tayebi M., Collinge J., Hawke S. Unswitched immunoglobulin M response prolongs mouse survival in prion disease. J. Gen. Virol. 2009, 90:777-782.
30. Thakker D.R., Weatherspoon M.R., Harrison J., Keene T.E., Lane D.S., Kaemmerer W.F., Stewart G.R., Shafer L.L. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4501-4506.
31. Vetrugno V., Cardinale A., Filesi I., Mattei S., Sy M.S., Pocchiari M., Biocca S. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun. 2005, 338:1791-1797.
32. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., Anstee D., Collinge J., Hawke S. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003, 422:80-83.
33. Wuertzer C.A., Sullivan M.A., Qiu X., Federoff H.J. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther. 2008, 16:481-486.
34. Zuber C., Knackmuss S., Rey C., Reusch U., Rottgen P., Frohlich T., Arnold G.J., Pace C., Mitteregger G., Kretzschmar H.A., Little M., Weiss S. Single chain Fv antibodies directed against the 37kDa/67kDa laminin receptor as therapeutic tools in prion diseases. Mol. Immunol. 2008, 45:144-151.
35. Zuber C., Mitteregger G., Schuhmann N., Rey C., Knackmuss S., Rupprecht W., Reusch U., Pace C., Little M., Kretzschmar H.A., Hallek M., Buning H., Weiss S. Delivery of single-chain antibodies (scFvs) directed against the 37/67kDa laminin receptor into mice via recombinant adeno-associated viral vectors for prion disease gene therapy. J. Gen. Virol. 2008, 89:2055-2061.